Human — controlled trial

Tirzepatide Once Weekly for the Treatment of Obesity

Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more a…

Cited by

Tirzepatide
What the research on Tirzepatide actually shows
The indexed literature on Tirzepatide includes human clinical or observational records (5 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Tirzepatide is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.

Compounds examined

Tirzepatide

Study records state what a paper reported. PepIndex does not interpret findings, assess clinical significance, or restate results in language implying an application not present in the source. Last reviewed 23 Jul 2026.